<div class="pk-crumbs" data-crumbs="[{&quot;label&quot;:&quot;Drugs&quot;,&quot;href&quot;:&quot;README.md&quot;},{&quot;label&quot;:&quot;C01D&quot;,&quot;href&quot;:&quot;atc/C01D.md&quot;},{&quot;label&quot;:&quot;molsidomine&quot;}]"></div>

# molsidomine

- **generic name:** molsidomine
- **ATC codes:** `C01DX12`
- **DrugBank:** [DB09282](https://go.drugbank.com/drugs/DB09282) · **PubChem:** [CID 5353788](https://pubchem.ncbi.nlm.nih.gov/compound/5353788)
- **molar mass:** 242.235 g/mol (C9H14N4O4) — DrugBank
- **groups:** approved, withdrawn

## About

Molsidomine is a vasodilator drug that was used to treat heart conditions such as angina. It was once approved but has been withdrawn from use in many places, and is no longer authorised in the European Union.

<small>Summary written by `glm-5.3-flash` from [Wikidata Q408132](https://www.wikidata.org/wiki/Q408132) and the WHO ATC classification; not checked by a person.</small>

## Extraction summary

| extracted at | time | popPK e/r/o | PD e/r/o (paper) | PGx e/r/o | tokens in/out | LLM | papers | GROBID/JATS | OA/non-OA | NONMEM |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-20 20:16 | 18:49 | 0/0/0 | 0/0/0 | 0/0/0 | 222,463/11,608 | ollama / qwen3.8:27b-mtp-q8_0 | 3 | 2/4 | 3/0 | 0 |

## popPK records

_not available_

## ADME sites

Where this drug is handled, from DrugBank's curated enzymes / transporters / carriers and the KB's PGx genes, mapped to tissue through the ADME gene table. Compare it with other drugs on the [Sites & interactions](sites?drugs=molsidomine) page (add drugs there; the set becomes a link).

| process | tissue | actors (role) | evidence |
|---|---|---|---|
| metabolism | liver | <sub>named in DrugBank's ADME text</sub> | prose |
| metabolism | small intestine | <sub>named in DrugBank's ADME text</sub> | prose |

<sub>Actors without a tissue in the table: GUCY1A2 (inducer), GUCY1A2 (target), PDE5A (substrate).</sub>

<details class="legend">
<summary>Badge legend — what each badge means</summary>
<table><thead><tr><th>badge</th><th>what it means</th></tr></thead><tbody><tr><td><span class="pk-badge pk-badge--green">curated</span></td><td>hand-authored by a person — an exemplar, not an extraction.</td></tr><tr><td><span class="pk-badge pk-badge--green">extracted</span></td><td>the pipeline accepted the record: every closed-form check it could run passed.</td></tr><tr><td><span class="pk-badge pk-badge--green">reviewed — candidate</span></td><td>the reviewer ran the built model against the paper's own reported values and they agree — the best automatic verdict there is.</td></tr><tr><td><span class="pk-badge pk-badge--green">accepted (caveats)</span></td><td>the model replicates the paper, but an advisory check failed — the record page names the caveat under the badge and the drug page shows it under the status.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>extracted, then a check failed or a value looks implausible. The numbers are shown as read, not endorsed.</td></tr><tr><td><span class="pk-badge pk-badge--orange">built, not shipped</span></td><td>a model was built, but a core parameter fell back to a library default, so it is not shipped.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted — the record is not a compartmental model, or nothing usable was extracted.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">not modelled</span></td><td>pipeline state, not a judgement: no model has been built for this record yet (likewise `not simulated`).</td></tr><tr><td><span class="pk-badge pk-badge--stale">stale</span></td><td>the reviewer's verdict predates the latest re-run of the paper — treat the status as out of date, not as current.</td></tr><tr><td><span class="pk-badge pk-badge--green">cross-checked ✓</span></td><td>every independent reader agreed on every compared field. With more than one reader the badge counts them, e.g. 'cross-checked ✓ 2/2'.</td></tr><tr><td><span class="pk-badge pk-badge--orange">cross-check: partial</span></td><td>a reader differs on a non-structural field (a population label, a flag), or the readers do not all agree with each other.</td></tr><tr><td><span class="pk-badge pk-badge--red">cross-check: disputed</span></td><td>at least one reader differs on a structural parameter — a clearance, a volume, ka, a lag. The record still holds the FIRST reading; the disagreement is a signal for a reviewer, never an automatic correction.</td></tr><tr><td><span class="pk-badge pk-badge--species">rat</span></td><td>the data come from an animal (or in-vitro) study, not from people. The record, its model and its simulation are kept — they describe that species.</td></tr></tbody></table>
<p><small>The first badge is the record's <b>status</b> — what the pipeline and the reviewer concluded. A second badge, when present, is the <b>cross-check</b>: whether a model of another family, re-reading the same paper, extracted the same numbers. They are independent — a rejected record can be cross-checked, and a confirmed reading can still fail a plausibility check.</small></p>
</details>

## Coverage

- **PubMed hits:** 92 matched, 93 returned
- **screened:** 5  ·  **relevant:** 5
- **records:** 0  ·  extracted 0  ·  needs_review 0  ·  rejected 0  ·  stale 0
- **scholar-agent fallback query used:** True

## Full text wanted

_12 paper(s) judged relevant from the abstract, with no full text on disk — paywalled, or the resolver could not reach them. Follow the DOI, then save the PDF into `papers/` as `&lt;save as&gt;.pdf` and re-run the extraction._

| save as | citation | domain | score | DOI | PubMed | why wanted |
|---|---|---|---|---|---|---|
| `Spreux-Varoquaux_1991.pdf` | Spreux-Varoquaux O et al., Pharmacokinetics of molsidomine and its…, British journal of clinical… (1991) | popPK | 10 | [10.1111/j.1365-2125.1991.tb03919.x](https://doi.org/10.1111/j.1365-2125.1991.tb03919.x) | [1777378](https://pubmed.ncbi.nlm.nih.gov/1777378) | The evidence explicitly reports quantitative pharmacokinetic parameters (half-life and apparent plasma clearance) for molsidomine in both healthy volunteers and patients with liver cirrhosis. |
| `Spreux-Varoquaux_1991_2.pdf` | Spreux-Varoquaux O et al., Pharmacokinetics of molsidomine and of…, Fundamental & clinical phar… (1991) | popPK | 10 | [10.1111/j.1472-8206.1991.tb00741.x](https://doi.org/10.1111/j.1472-8206.1991.tb00741.x) | [1955198](https://pubmed.ncbi.nlm.nih.gov/1955198) | The study reports quantitative pharmacokinetic parameters (clearance, half-life) for molsidomine in humans, with specific numeric values provided in the text. |
| `Ostrowski_1985.pdf` | Ostrowski J et al., Pharmacokinetics of molsidomine in huma…, American heart journal (1985) | popPK | 9 | [10.1016/0002-8703(85)90670-2](https://doi.org/10.1016/0002-8703(85)90670-2) | [3838399](https://pubmed.ncbi.nlm.nih.gov/3838399) | The paper reports quantitative PK parameters for molsidomine including half-life (1.6 +/- 0.8 h), peak concentration, and bioavailability, which are directly readable in the provided text. |
| `Bergstrand_1984.pdf` | Bergstrand R et al., Intravenous and oral administration of…, European journal of clinica… (1984) | popPK | 8 | [10.1007/BF00544046](https://doi.org/10.1007/BF00544046) | [6548711](https://pubmed.ncbi.nlm.nih.gov/6548711) | The study reports PK parameters for molsidomine, but the evidence only provides a qualitative description and a single bioavailability value, lacking the specific numeric values for clearance, volume, or half-life required for extraction. |
| `Meinertz_1985.pdf` | Meinertz T et al., Relationship between pharmacokinetics a…, American heart journal (1985) | popPK | 8 | [10.1016/0002-8703(85)90671-4](https://doi.org/10.1016/0002-8703(85)90671-4) | [3838400](https://pubmed.ncbi.nlm.nih.gov/3838400) | The paper is a pharmacokinetic study of molsidomine in humans, but the provided evidence contains only qualitative descriptions and no numeric parameter values. |
| `Singlas_1983.pdf` | Singlas E et al., [Human pharmacokinetics of molsidomine], Annales de cardiologie et d… (1983) | popPK | 8 | not captured | [6364946](https://pubmed.ncbi.nlm.nih.gov/6364946) | The text provides specific quantitative PK parameters for molsidomine, including volume of distribution (1 L/kg), half-life (1-2 hours), and bioavailability (60%). |
| `Wildgrube_1986.pdf` | Wildgrube HJ et al., Liver function and pharmacokinetics of…, Arzneimittel-Forschung (1986) | popPK | 8 | not captured | [3768083](https://pubmed.ncbi.nlm.nih.gov/3768083) | The paper is a PK study of molsidomine, but the specific numeric parameter values are not present in the provided evidence text. |
| `Wilson_1987.pdf` | Wilson ID et al., The metabolism of [14C]N-ethoxycarbonyl…, Xenobiotica; the fate of fo… (1987) | popPK | 8 | [10.3109/00498258709047179](https://doi.org/10.3109/00498258709047179) | [3825179](https://pubmed.ncbi.nlm.nih.gov/3825179) | The study reports quantitative PK parameters for molsidomine including Cmax, Tmax, and half-life, but lacks explicit clearance or volume of distribution values. |
| `Kuhn_1989.pdf` | Kuhn M et al., Endothelium-dependent vasodilatation in…, Journal of cardiovascular p… (1989) | pd | 5 | not captured | [2484699](https://www.ncbi.nlm.nih.gov/pubmed/2484699) | metadata signals extractable PD data (EC50) |
| `Nunez_1987.pdf` | Nunez D et al., [Effects of SIN-1, a metabolite of mols…, Pathologie-biologie (1987) | pd | 4 | not captured | [3550639](https://www.ncbi.nlm.nih.gov/pubmed/3550639) | metadata signals extractable PD data (IC50) |
| `Robak_1993.pdf` | Robak J et al., Nitric oxide donors as generators and s…, Polish journal of pharmacol… (1993) | pd | 4 | not captured | [8401759](https://www.ncbi.nlm.nih.gov/pubmed/8401759) | metadata signals extractable PD data (IC50) |
| `Zembowicz_1990.pdf` | Zembowicz A et al., Vasorelaxant and platelet-suppressant p…, Polish journal of pharmacol… (1990) | pd | 4 | not captured | [2124687](https://www.ncbi.nlm.nih.gov/pubmed/2124687) | metadata signals extractable PD data (EC50) |

<sub>queue written 2026-09-20T20:14:18.842021+00:00</sub>

## Screened and excluded

| domain | paper | verdict | relevance | extractability | reason |
|---|---|---|---|---|---|
| popPK | Bergstrand_1984 | relevant | 8 | 2 | The study reports PK parameters for molsidomine, but the evidence only provides a qualitative description and a single bioavailability value, lacking the specific numeric values for clearance, volume, or half-life required for extraction. |
| popPK | Berkenboom_1989 | irrelevant | 0 | 0 | The study is an in-vitro pharmacological investigation of vascular relaxation mechanisms, not a pharmacokinetic study, and reports no disposition parameters for molsidomine. |
| popPK | Blasini_1984 | irrelevant | 2 | 0 | The study focuses on anti-ischemic efficacy and bioavailability comparisons without reporting specific quantitative PK parameters like clearance, volume, or half-life in the provided text. |
| popPK | Bongartz_2010 | irrelevant | 0 | 0 | The study is a pharmacodynamic assessment of cardiac function in rats and does not report any pharmacokinetic parameters for molsidomine. |
| popPK | Brockmeier_1981 | irrelevant | 0 | 0 | The paper focuses on in-vitro dissolution modeling and does not report in-vivo pharmacokinetic parameters for molsidomine. |
| popPK | Bult_1995 | irrelevant | 0 | 0 | The study is a mechanistic investigation of atherosclerosis and vascular reactivity in rabbits, not a pharmacokinetic study, and reports no disposition parameters for molsidomine. |
| PD | Bult_1995 | not_relevant | 3 | 2 | The study reports qualitative changes in sensitivity (pD2) and efficacy (Emax) of agonists in tissue segments but does not provide a concentration-effect curve or numeric PD parameters for molsidomine itself. |
| popPK | Chander_2005 | irrelevant | 0 | 0 | The study is a mechanistic investigation of molsidomine's renoprotective effects against cyclosporine nephrotoxicity and does not report any pharmacokinetic parameters. |
| popPK | Combis_1996 | irrelevant | 0 | 0 | The study is a hemodynamic evaluation of molsidomine's effect on portal hypertension and does not report pharmacokinetic parameters such as clearance, volume, or half-life. |
| PD | Dalloz_1997 | not_relevant | 2 | 1 | The paper reports an IC50 for sodium nitroprusside (SNP) but explicitly states that molsidomine did not produce detectable NO or superoxide scavenging effects, providing no numeric PD parameters for molsidomine. |
| popPK | Das_2014 | irrelevant | 0 | 0 | The paper is an in-vitro mechanistic study on endothelial cells and does not involve molsidomine or pharmacokinetic parameters. |
| popPK | Fach_1984 | irrelevant | 2 | 0 | The study reports pharmacodynamic endpoints (ST-segment depression) and peak plasma concentrations (Cmax) but does not provide quantitative disposition parameters such as clearance, volume of distribution, or half-life. |
| popPK | Filip_1998 | irrelevant | 0 | 0 | The study is a behavioral pharmacology experiment in rats where molsidomine is used as a co-administered NO donor to modulate psychostimulant effects, not a pharmacokinetic study reporting disposition parameters. |
| popPK | García-Pagán_1996 | irrelevant | 0 | 0 | The study is a hemodynamic/clinical trial assessing portal hypertension treatment, not a pharmacokinetic study, and reports no PK parameters for molsidomine. |
| popPK | Gong_2020 | irrelevant | 0 | 0 | The study focuses on the population pharmacokinetics of tacrolimus, and molsidomine is only mentioned in the introduction as an example of a drug with reduced clearance in heart failure, with no PK parameters reported for it. |
| PD | Gong_2020 | not_relevant | 0 | 0 | The paper reports a population pharmacokinetic (PK) model for tacrolimus, not molsidomine, and contains no pharmacodynamic (PD) or exposure-response analysis. |
| PGx | Gourgiotis_2012 | not_relevant | 0 | 0 | The paper investigates the pharmacological interaction between nitric oxide modulators and apomorphine in rats, not the effect of a gene variant on molsidomine's PK or PD. |
| popPK | Huber_1992 | irrelevant | 0 | 0 | no_text gate: only 119 chars of text extracted (&lt; 400) |
| popPK | Impagnatiello_2011 | irrelevant | 0 | 0 | Molsidomine is used only as a comparator agent in an ocular pharmacodynamics study, with no population pharmacokinetic parameters reported. |
| PD | Impagnatiello_2011 | not_relevant | 3 | 2 | The paper reports a qualitative dose-dependent effect for molsidomine but provides no numeric PD parameters (e.g., EC50, Emax) or concentration-effect data for molsidomine itself. |
| popPK | Jean_2002 | irrelevant | 0 | 0 | The study investigates the effects of nitric oxide inhalation on bacterial clearance in rats and does not involve molsidomine or pharmacokinetic parameters. |
| popPK | Kanazawa_1999 | irrelevant | 0 | 0 | The study investigates the pharmacological effects of peroxynitrite on airway function in guinea pigs and does not involve molsidomine or report any pharmacokinetic parameters. |
| popPK | Khiabani_2002 | irrelevant | 0 | 0 | The study investigates the effects of the nitric oxide donor SIN-1 on flap survival in pigs and does not involve molsidomine or report any pharmacokinetic parameters. |
| popPK | Koyani_2015 | irrelevant | 0 | 0 | The paper is a mechanistic in-vitro study on myeloperoxidase and peroxynitrite, with no mention of molsidomine or pharmacokinetic parameters. |
| popPK | Kuhn_1989 | irrelevant | 0 | 0 | no_text gate: only 136 chars of text extracted (&lt; 400) |
| PD | Kuhn_1989 | not_relevant | 0 | 0 | The paper investigates the effects of glyceryl trinitrate and SIN-1, not molsidomine. |
| popPK | Lehmann_1998 | irrelevant | 2 | 0 | The study is a clinical efficacy comparison focusing on anti-ischemic effects and hemodynamics, and while it mentions plasma concentrations, it does not report quantitative pharmacokinetic parameters (CL, V, ka, etc.) for molsidomine. |
| popPK | Lenaerts_2011 | irrelevant | 0 | 0 | The study is a mechanistic electrophysiology investigation in sheep where molsidomine is used as a nitric oxide donor, and no pharmacokinetic parameters are reported. |
| PD | Lorenc-Koci_2017 | not_relevant | 2 | 1 | The study reports qualitative blood pressure changes following a fixed dose of molsidomine but does not provide concentration-effect data, dose-response curves, or numeric PD parameters (e.g., Emax, EC50). |
| popPK | Meinertz_1985 | relevant | 8 | 0 | The paper is a pharmacokinetic study of molsidomine in humans, but the provided evidence contains only qualitative descriptions and no numeric parameter values. |
| popPK | Messin_2003 | relevant | 4 | 2 | The study reports qualitative PK descriptions and concentration ranges (e.g., 15-20 ng/ml) but lacks specific quantitative disposition parameters like clearance, volume, or half-life. |
| popPK | Meyer_1998 | irrelevant | 0 | 0 | The study is a behavioral pharmacology experiment in rats where molsidomine is used as a nitric oxide donor to test learning impairment, not a pharmacokinetic study reporting disposition parameters. |
| popPK | Muramatsu_1983 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of vasorelaxing actions on isolated blood vessels and does not report pharmacokinetic parameters. |
| PD | Noack_1989 | not_relevant | 4 | 2 | The paper describes a biochemical concentration-response relationship between SIN-1 (molsidomine metabolite) and guanylate cyclase activation, but the provided text lacks specific numeric PD parameters (e.g., EC50 values, Emax) or a quantitative curve, making them not extractable from this snippet. |
| popPK | Ogawa_2013 | irrelevant | 2 | 0 | The paper is a review that mentions molsidomine only as one of several drugs with reduced clearance in heart failure, without providing specific quantitative PK parameter values for molsidomine. |
| popPK | Ogawa_2014 | irrelevant | 2 | 0 | This is a review article that discusses molsidomine qualitatively as one of many drugs with altered PK in heart failure, but it does not provide specific quantitative PK parameter values (CL, V, etc.) for molsidomine in the provided text. |
| PD | Ostrowski_1985 | not_relevant | 2 | 0 | The paper reports only pharmacokinetic parameters and qualitatively mentions a correlation with pharmacodynamic data, but provides no numeric PD parameters or concentration-effect curves. |
| popPK | Ostrowski_1985_2 | irrelevant | 2 | 0 | The provided evidence is only the abstract/introduction which describes the study's aim but contains no quantitative pharmacokinetic parameter values (CL, V, ka, etc.) for molsidomine. |
| popPK | Pitsikas_2003 | irrelevant | 0 | 0 | The study is a behavioral pharmacology experiment investigating memory in rats and does not report any pharmacokinetic parameters for molsidomine. |
| popPK | Pitsikas_2003_2 | irrelevant | 0 | 0 | The study is a behavioral pharmacology experiment investigating memory in rats, where molsidomine is used as a nitric oxide donor to modulate GABA(B) receptor effects, and no pharmacokinetic parameters are reported. |
| popPK | Pitsikas_2005 | irrelevant | 0 | 0 | The study is a behavioral pharmacology experiment in rats where molsidomine is used as a nitric oxide donor to modulate 5-HT1A receptor effects, not a pharmacokinetic study reporting disposition parameters. |
| PD | Pitsikas_2005 | not_relevant | 2 | 1 | The paper reports qualitative dose-response effects of molsidomine on behavioral outcomes but does not provide numeric PD parameters (e.g., EC50, Emax) or a quantitative concentration-effect model. |
| popPK | Pitsikas_2007 | irrelevant | 0 | 0 | The study is a behavioral pharmacology investigation of memory in rats where molsidomine is used as a co-administered agent, and no pharmacokinetic parameters are reported. |
| PD | Pitsikas_2007 | not_relevant | 2 | 1 | The paper reports a qualitative behavioral interaction between memantine and molsidomine at fixed doses but does not provide a concentration-effect curve, dose-response curve for molsidomine alone, or any numeric PD parameters (e.g., EC50, Emax). |
| popPK | Porst_2004 | irrelevant | 0 | 0 | The paper is a review of PDE5 inhibitors where molsidomine is only mentioned as a contraindicated co-medication, with no pharmacokinetic parameters reported. |
| popPK | Rangan_2001 | irrelevant | 0 | 0 | The study is a mechanistic investigation of molsidomine's effect on renal inflammation in rats and does not report any pharmacokinetic parameters. |
| PD | Rehse_1993 | not_relevant | 3 | 2 | The paper reports IC50 values for new sydnone imines and qualitatively compares the hemodynamic effects of one compound to molsidomine, but it does not provide numeric PD parameters or an exposure-response curve for molsidomine itself. |
| popPK | Rietbrock_1992 | irrelevant | 2 | 0 | The study reports bioavailability and qualitative profile features (peaks, dissolution) but lacks quantitative compartmental PK parameters (CL, V, ka) for molsidomine. |
| PD | Robak_1993 | not_relevant | 0 | 0 | The paper explicitly states that molsidomine did not exert any of the studied in vitro activities (NO generation, superoxide scavenging, etc.), so no PD relationship or parameters are reported for it. |
| popPK | Rosenkranz_1996 | irrelevant | 2 | 1 | The text is a review summarizing general pharmacokinetic properties (ranges for tmax, bioavailability, t1/2, Vd) without reporting specific quantitative clearance (CL) values or a compartmental/population-PK model for molsidomine. |
| PD | Rudolph_1991 | not_relevant | 1 | 0 | The text is a qualitative review comparing the mechanisms and clinical profiles of nitrates and molsidomine, containing no numeric PD parameters, concentration-effect curves, or quantitative exposure-response data. |
| popPK | Röhl_1980 | irrelevant | 2 | 1 | The study is a pharmacodynamic/ergometric trial that reports only a single half-life value without a corresponding volume of distribution or compartmental model parameters. |
| popPK | Schütte_1997 | irrelevant | 0 | 0 | The study is a mechanistic/pharmacodynamic investigation of pulmonary vasodilation in buffer-perfused rabbit lungs and does not report quantitative pharmacokinetic parameters (CL, V, ka, etc.) for molsidomine. |
| PGx | Schütte_1997 | not_relevant | 0 | 0 | The study investigates the pharmacodynamics of aerosolized NO donors in an animal model and does not report any pharmacogenomic effects or gene variant associations. |
| popPK | Sennesael_1993 | irrelevant | 0 | 0 | The study investigates linsidomine (SIN 1), not molsidomine. |
| popPK | Shafiee_2003 | irrelevant | 0 | 0 | The paper is an in-vitro study on the antioxidant properties of grape and olive extracts and does not involve molsidomine or pharmacokinetic parameters. |
| PGx | Sinha_2021 | not_relevant | 0 | 0 | The paper investigates the effect of a nitric oxide donor (NCX-4040) on drug resistance mechanisms (ABC transporters) and does not report pharmacogenomic effects on the PK/PD of molsidomine. |
| popPK | Ulrich_2014 | irrelevant | 0 | 0 | The paper is a mechanistic study on antiphospholipid antibodies where molsidomine is used only as a NO donor to test biological effects, not as a subject of pharmacokinetic analysis. |
| popPK | Unger_1993 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of nitrate tolerance in isolated rat aorta, not a pharmacokinetic study, and molsidomine is only mentioned via its metabolite. |
| popPK | Vandenbossche_1993 | irrelevant | 0 | 0 | The study investigates chemical stability (degradation half-life) of molsidomine in infusion fluids, not pharmacokinetic disposition parameters in a biological system. |
| popPK | Vapaatalo_1994 | irrelevant | 0 | 0 | The paper is a review of NO-donors in cardiology and does not report original quantitative pharmacokinetic parameters for molsidomine. |
| PD | Vapaatalo_1994 | not_relevant | 1 | 0 | The text is a general review of NO-donors in cardiology that mentions molsidomine qualitatively but provides no specific pharmacodynamic data, exposure-response curves, or numeric PD parameters. |
| popPK | Verscheijden_2021 | irrelevant | 0 | 0 | The paper focuses on the pharmacokinetics of morphine, not molsidomine. |
| PD | Verscheijden_2021 | not_relevant | 0 | 0 | The paper reports a PBPK/PD model for morphine, not molsidomine. |
| popPK | Vinel_1990 | irrelevant | 0 | 0 | The study evaluates hemodynamic effects (blood pressure, flow) rather than pharmacokinetic disposition parameters (CL, V, t1/2) for molsidomine. |
| popPK | Weber_1985 | irrelevant | 0 | 0 | The paper is a review of vasodilator classification and does not report quantitative pharmacokinetic parameters for molsidomine. |
| popPK | Weber_1987 | irrelevant | 0 | 0 | The text is a clinical review of molsidomine's therapeutic effects and mechanism, containing no quantitative pharmacokinetic parameters. |
| PD | Weber_1987 | not_relevant | 1 | 0 | The text is a qualitative review of molsidomine's mechanism and clinical efficacy, containing no numeric PD parameters, concentration-effect data, or dose-response curves. |
| PD | Weber_1988 | not_relevant | 1 | 0 | The text is a qualitative review discussing the mechanism of tolerance and suggesting future trials, without providing any numeric PD parameters or concentration-effect data. |
| popPK | Wildgrube_1986 | relevant | 8 | 0 | The paper is a PK study of molsidomine, but the specific numeric parameter values are not present in the provided evidence text. |
| popPK | Wilson_1986 | irrelevant | 2 | 0 | The study focuses on metabolic identification and excretion of radiolabel in animals, reporting no quantitative pharmacokinetic parameters (CL, V, ka) for molsidomine. |
| popPK | Zembowicz_1990 | irrelevant | 0 | 0 | no_text gate: only 65 chars of text extracted (&lt; 400) |
| PD | Zembowicz_1990 | not_relevant | 0 | 0 | The provided text is only a title and does not contain the full text, data, or numeric PD parameters required to assess the exposure-response relationship. |
| popPK | Zordan_2013 | irrelevant | 0 | 0 | The paper is a mechanistic study on the immunomodulatory effects of molsidomine in a mouse model of muscular dystrophy and does not report any pharmacokinetic parameters. |
| popPK | unknown_1994 | irrelevant | 0 | 0 | The provided evidence contains no mention of molsidomine or its pharmacokinetic parameters. |
| PD | unknown_1994 | not_relevant | 0 | 0 | The provided text is only a title and file description for a conference abstract collection, containing no specific data, models, or numeric parameters for molsidomine. |

---
<sub>Generated by `docs.py` (scholarv2)</sub>
